Patent ID: 11858931
Assignee: PLIANT THERAPEUTICS, INC.
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC C

Claim 7:
8. The method of claim 5, wherein:
the subject has or is at risk of a fibrotic disease selected from the group consisting of: idiopathic pulmonary fibrosis (IPF), interstitial lung disease, radiation-induced pulmonary fibrosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic liver disease induced fibrosis, Alport syndrome, primary sclerosing cholangitis (PSC), primary biliary cholangitis, biliary atresia, systemic sclerosis associated interstitial lung disease, scleroderma, diabetic nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis, chronic kidney disease, and Crohn's Disease; and
the method comprises inhibiting one or both of αVβ1 integrin and αVβ6 integrin in the subject, thereby treating the fibrotic disease in the subject.